ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company’s primary product candidate, Gencaro (bucindolol hydrochloride), is a pharmacologically beta-blocker and mild vasodilator that it is evaluating in a clinical trial for the treatment of atrial fibrillation, in patients with heart failure and left ventricular systolic dysfunction. The company is testing hypothesis in a Phase 2B/3 clinical trial of Gencaro, known as GENETIC-AF. Strategy The key elements of the company’s strategy are to advance the development of Gencaro; build a cardiovascular pipeline; and leverage its existing assets. Research and Development For the year ended December 31, 2014, the company’s research and development expenses totaled $5.6 million.
arca biopharma inc (ABIO:NASDAQ CM)
11080 CirclePoint Road
Westminster, CO 80020
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for ABIO.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.